Health Care & Life Sciences » Biotechnology | Nektar Therapeutics

Nektar Therapeutics

Nektar Therapeutics
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
172.47 M
Public Float
88.95 M
Nektar Therapeutics
Stock Exchange NASDAQ Stock Market
EPS
$3.52
Market Cap
$6.13 B
Shares Outstanding
174.31 M
Public Float
171.2 M

Profile

Address
455 Mission Bay Boulevard South
San Francisco California 94158
United States
Employees -
Website http://www.nektar.com
Updated 07/08/2019
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. It operates through the United States and Europe geogrpahical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.

Financials

View All
Created with Highcharts 5.0.14Nektar TherapeuticsNet Income. Fiscal year is January-December. All values USD Thousands.162 013162 01353 91653 91681 17781 177153 524153 52496 69296 692681681201320142015201620172018050k100k150k200k
Created with Highcharts 5.0.14Nektar TherapeuticsSales/Revenue. Fiscal year is January-December. All values USD Thousands.148 921148 921200 707200 707230 784230 784165 436165 436307 711307 7111 1931 1932013201420152016201720180100k200k300k400k

Howard W. Robin
President, Chief Executive Officer & Director
Robert B. Chess
Chairman